A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia

Eddy Fadlyana; Kusnandi Rusmil; Rodman Tarigan; Andri Reza Rahmadi; Susantina Prodjosoewojo; Yulia Sofiatin; Citra V. Khrisna; Rini Mulia Sari; Lilis Setyaningsih; Fikrianti Surachman; Novilia Sjafri Bachtiar; Hadyana Sukandar; Imam Megantara; Chrysanti Murad; Krisna Nur A. Pangesti; Vivi Setiawaty; Sunarjati Sudigdoadi; Yaling Hu; Qiang Gao; Cissy B. Kartasasmita

A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia

Vaccine (2021) - Comments
pubmed: 34620531 doi: 10.1016/j.vaccine.2021.09.052 issn: 0264-410x issn: 1873-2518

Eddy Fadlyana, Kusnandi Rusmil, Rodman Tarigan, Andri Reza Rahmadi, Susantina Prodjosoewojo, Yulia Sofiatin, Citra V. Khrisna, Rini Mulia Sari, Lilis Setyaningsih, Fikrianti Surachman, Novilia Sjafri Bachtiar, Hadyana Sukandar, Imam Megantara, Chrysanti Murad, Krisna Nur A. Pangesti, Vivi Setiawaty, Sunarjati Sudigdoadi, Yaling Hu, Qiang Gao, Cissy B. Kartasasmita